A prospective exploratory clinical study of penpulimab plus anlotinib as first-line treatment for locally advanced or metastatic urothelial carcinoma.

被引：0
|
作者：
Yang, Bo
Xiong, Qi
Song, Qi
Long, Yaping
Guo, Gang
Li, Hongzhao
机构：
[1] Chinese Peoples Liberat Army Gen Hosp, First Med Ctr, Dept Oncol, Beijing, Peoples R China
[2] Chinese Peoples Liberat Army Gen Hosp, Dept Oncol, Beijing, Peoples R China
[3] Chinese Peoples Liberat Army Gen Hosp, Dept Med Oncol, Beijing, Peoples R China
[4] Med Ethics Comm Chinese PLA Gen Hosp, Beijing, Peoples R China
[5] Chinese Peoples Liberat Army Gen Hosp, First Med Ctr, Dept Urol, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4567
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Avelumab as First-Line Maintenance Treatment in Locally Advanced or Metastatic Urothelial Carcinoma
    Mansinho, Andre
    Cruz, Andreia
    Marconi, Lorenzo
    Pinto, Cidalia
    Augusto, Isabel
    ADVANCES IN THERAPY, 2023, 40 (10) : 4134 - 4150
  • [2] Avelumab as First-Line Maintenance Treatment in Locally Advanced or Metastatic Urothelial Carcinoma
    André Mansinho
    Andreia Cruz
    Lorenzo Marconi
    Cidália Pinto
    Isabel Augusto
    Advances in Therapy, 2023, 40 : 4134 - 4150
  • [3] Updated results from a phase II study of penpulimab plus anlotinib as first-line therapy in metastatic urothelial cancer (mUC)
    Yang, Bo
    Xiong, Qi
    Song, Qi
    Long, Yaping
    Guo, Gang
    Li, Hongzhao
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [4] Penpulimab plus gemcitabine in combination with cisplatin or anlotinib as first-line treatment for metastatic nasopharyngeal carcinoma (M NPC): A phase II study.
    Huang, Shuang
    Chen, Xiaozhong
    Qu, Song
    Qu, Shenhong
    Han, Yaqian
    Yang, Kunyu
    Huang, Shiting
    Li, Min
    Zhang, Lin
    Ding, Qian
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E18032 - E18032
  • [5] Anlotinib combined with penpulimab and hepatic artery infusion chemotherapy (HAIC) in the first-line treatment of unresectable hepatocellular carcinoma.
    Chen, Gong-Rang
    Zhong, Ting
    Cai, Jian-Hua
    Liang, Juan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : TPS579 - TPS579
  • [6] Gemcitabine plus docetaxel as first-line biweekly therapy in locally advanced and/or metastatic urothelial carcinoma: a phase II study
    Neri, Bruno
    Vannini, Laura
    Giordano, Clara
    Grifoni, Raffaella
    Pantaleo, Pietro
    Baldazzi, Valentina
    Crisci, Alfonso
    Lapini, Alberto
    Raugei, Andrea
    Carini, Marco
    ANTI-CANCER DRUGS, 2007, 18 (10) : 1207 - 1211
  • [7] Patient Preferences for First-Line Treatment of Locally Advanced or Metastatic Urothelial Carcinoma: An Application of Multidimensional Thresholding
    Apolo, Andrea B.
    Michaels-Igbokwe, Christine
    Simon, Nicholas I.
    Benjamin, David J.
    Farrar, Mallory
    Hepp, Zsolt
    Mucha, Lisa
    Heidenreich, Sebastian
    Cutts, Katelyn
    Krucien, Nicolas
    Ramachandran, Natasha
    Gore, John L.
    PATIENT-PATIENT CENTERED OUTCOMES RESEARCH, 2024, : 77 - 87
  • [8] First-Line Therapy in locally advanced or metastatic Urothelial Cancer
    Rexer, H.
    ONKOLOGE, 2012, 18 (01): : 70 - 71
  • [9] First-Line Therapy in locally advanced or metastatic Urothelial Cancer
    Rexer, H.
    ONKOLOGE, 2011, 17 (07): : 638 - 639
  • [10] Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice
    Grivas, Petros
    Agarwal, Neeraj
    Pal, Sumanta
    Kalebasty, Arash Rezazadeh
    Sridhar, Srikala S.
    Smith, Jodi
    Devgan, Geeta
    Sternberg, Cora N.
    Bellmunt, Joaquim
    CANCER TREATMENT REVIEWS, 2021, 97
12345